DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Drugmaker - 1 Teva - 1 Jonathan Kanter - 1 Glenmark - 1 Apotex - 1
Top related locs:
Eastern District
Top related orgs:
Drugmaker Teva Pharmaceuticals - 1 Department of Justice - 1 Glenmark Pharmaceuticals - 1 Antitrust Division - 1 DOJ - 1 Eastern District of Pennsylvania - 1 Apotex Corp - 1

Search resuls for: "Drugmaker Teva Pharmaceuticals"


2 mentions found


☆ Teva to pay $225 million in fines and divest generic drug to resolve price-fixing charges
  + stars: | 2023-08-21 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +3 min
Drugmaker Teva Pharmaceuticals agreed to pay $225 million in criminal fines over five years and divest its version of a generic cholesterol drug to resolve charges related to price-fixing on that medication and other widely used treatments, the Department of Justice announced Monday. Teva, in a press release Monday, said it will pay $22.5 million each year from 2024 through 2027, and $135 million in 2028. Glenmark Pharmaceuticals will pay $30 million to resolve similar charges. Since 2020, the DOJ's antitrust division has charged five other pharmaceutical companies for participating in similar schemes affecting several generic drugs. Teva has also agreed to donate $50 million worth of two generic drugs affected by price-fixing to humanitarian organizations that provide medications to Americans in need.
Persons: Drugmaker, Teva, Jonathan Kanter, Glenmark, Apotex Organizations: Drugmaker Teva Pharmaceuticals, Department of Justice, Glenmark Pharmaceuticals, Antitrust Division, DOJ, Eastern District of Pennsylvania, Apotex Corp Locations: Eastern District
☆ US FDA approves first OTC opioid overdose reversal drug
  + stars: | 2023-03-29 | by ( ) www.reuters.com   time to read: +2 min
[1/2] A box of NARCAN nasal spray is photographed at an outpatient treatment center in Indiana, Pennsylvania, U.S. on August 9, 2017. The approval for OTC use of the naloxone-based nasal spray will help align the federal government's stance with states that have provisions to offer the drug without prescription at pharmacies. Drug-related overdose deaths in the United States rose about 15% year-over-year to more than 100,000 in 2021, as per official data. While the approval puts Emergent ahead in the OTC product race, analysts have said it is not likely to derive significant sales from the approval. Benchmark analyst Robert Wasserman said ahead of the approval that Narcan sales peaked in 2020 and have declined since.
0 next >>
Total: 2